HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
about
Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial [ISRCTN85429598]The role of statins as potential targets for bone formationOngoing clinical trials of the pleiotropic effects of statinsCalcyclin, a Ca2+ ion-binding protein, contributes to the anabolic effects of simvastatin on bone.Statins and bones.Determination of the antibacterial activity of simvastatin against periodontal pathogens, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans: An in vitro study.Bone mineral density and factors influencing it in Asian Indian population with type 2 diabetes mellitus.Risk factors for osteoporosis in Japan: is it associated with Helicobacter pylori?Statins and osteoporosis: a clinical review.Effects of tocotrienol and lovastatin combination on osteoblast and osteoclast activity in estrogen-deficient osteoporosisCollagen with simvastatin promotes cell metabolism in osteoblast-like SaOS-2 cells.Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients treated with bisphosphonates alone or in combination with pitavastatin over an 18-month follow-up after more than 4 years of treatment with bisphosphonatesEffects of Statins on Bone Mineral Density and Fracture Risk: A PRISMA-compliant Systematic Review and Meta-AnalysisThe effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells.Composite Hydrogels for Bone RegenerationStatin-induced Ras activation integrates the phosphatidylinositol 3-kinase signal to Akt and MAPK for bone morphogenetic protein-2 expression in osteoblast differentiation.Statins decrease bone turnover in postmenopausal women: a cross-sectional study.Effects of simvastatin gels on murine calvarial bone.Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing.Poncirin prevents bone loss in glucocorticoid-induced osteoporosis in vivo and in vitro
P2860
Q24803192-3140196E-0B5A-426D-8ED7-B6640526AE2EQ24806198-C02E037C-D54B-4983-A456-D72933AE50CBQ28219321-6619BBC8-F37F-499D-886B-DE126B8AB79AQ31048716-4782AB97-1BDA-47A0-9E5F-8A52434287ECQ33955458-C59D030D-D616-4C62-95B7-D14869AE3EFBQ34102813-FC6AC147-BBC0-483B-8EE9-4780C4F0822FQ34319701-7F1B997D-929A-4C8F-BD1A-A014813C02EEQ35173200-BAC1A379-9CA2-4764-BDDE-4BC4A99DFC03Q36070930-620760E0-F1CC-4B34-825E-B065DC87F23EQ36182395-7DE1D38E-71F9-4B56-A309-50BE8ED3B89CQ36307541-0AA93266-A500-4B79-A3A4-A2A1B891B51BQ36633241-7765EA92-FED0-4AA4-AE34-705014ACA425Q36988655-A150B04E-21B7-41E1-976B-C3B4B6E1A53CQ37433910-832CFD5F-5472-4CAF-9991-C3379F22AD70Q38887763-46466143-9098-4F1F-84EE-BEA6E593F3A2Q40192599-31898FD1-A27F-4EB3-AD02-78531AAE07D7Q44111068-8508CCBE-BF51-4D39-BE98-ACBC119B38CAQ44204937-B45E121F-5303-42C8-A646-9C2B33E6C8F4Q46318018-73E07E90-69D5-47DE-8B02-943AF8C7BF03Q58126673-A25C1B51-BA35-4827-89FD-D5FD94343BFB
P2860
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
@ast
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
@en
type
label
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
@ast
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
@en
prefLabel
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
@ast
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
@en
P2093
P356
P1476
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
@en
P2093
P304
P356
10.1210/JC.85.3.1137
P407
P577
2000-03-01T00:00:00Z